Epidemiological, therapeutic, cytogenetic, and molecular profile of chronic myeloid leukemia at the national reference university hospital of N’Djamena from 2010-2020, Chad

The aim is to determine the epidemiological and cytogenetic profile (Philadelphia chromosome: Ph1) bcr-abl gene in patients with chronic myeloid leukemia (CML) assess therapeutic response of hydroxy-urea Imatinib treatment. From January 1, 2010 December 30, 2020, an observational study for diagnostic analytical purposes was carried out 54 cases CML at National Reference University Hospital (CHU-RN) N’Djamena. All selected presented splenomegaly on physical examination. Significant differences were observed between proportion housewives (31.48%) civil servants (3.70%), emaciated (27.84%) those fever (3.70%) probabilities 0.001 respectively. Hyperleukocytosis ranged from 100,000-149,000 GB / mm3 (42.30%) platelet count 20,000 611,000 mm3. Polymorphic massive myeloma 30-80% cases, a medullary karyotype 33.33% Ph1 + chromosome 66.66% Ph1-, transcript transcribed b3 a2 treatment regimens were: Hydroxy-Urea (HU) prednisolone (60%), (40%). Partial hematological remission obtained 40% cases. condition that occurs all ages especially men our region. continuation this national level will allow public authorities achieve prevalence organize effective prevention early management.